Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ037
- Development stage
- Preclinical
- Lead developer
- Tuojie Biotech
- Modality
- Small Molecules
01
Overview
TJ037 is a small molecule drug candidate developed by Tuojie Biotech (拓界生物医药) that targets hypoxia-inducible factor (HIF). HIF is a transcription factor that plays a central role in the cellular response to low oxygen levels (hypoxia) by regulating genes involved in erythropoiesis, angiogenesis, and metabolism. While specific therapeutic indications for TJ037 are not explicitly detailed in the company's early-stage pipeline, HIF-targeting agents are commonly developed for the treatment of anemia (via HIF-prolyl hydroxylase inhibition) or various solid tumors (via HIF-1α or HIF-2α inhibition). TJ037 is part of Tuojie Biotech's small molecule research pipeline.
Beyond the preview
Go deeper on TJ037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ037.